Outcomes-based payments

Views & Analysis

The NHS is moving rapidly towards integrated care models – and outcomes-based deals with pharma will also play a role.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.